Company Overview - Yunnan Baiyao (SZ 000538) announced that on December 11, 2025, it will accept investor research from Guangdong Zhenyuan Private Equity Fund and others, with company representatives Zhang Yu, Yang Kexin, and Yu Yang participating in the reception and answering investor questions [1] Financial Performance - For the first half of 2025, Yunnan Baiyao's revenue composition is as follows: commercial sales accounted for 59.78%, industrial sales for 40.01%, other businesses for 0.1%, technical development services for 0.08%, and hotel and catering services for 0.03% [1] - As of the report date, Yunnan Baiyao's market capitalization is 99.6 billion yuan [1]

Group 1 - Yunnan Baiyao (SZ 000538) announced that on December 10, 2025, it will host a research meeting with five individual investors, with company representatives Zhang Yu, Yang Kexin, and Yu Yang participating [1] - For the first half of 2025, Yunnan Baiyao's revenue composition is as follows: commercial sales account for 59.78%, industrial sales for 40.01%, other businesses for 0.1%, technical development services for 0.08%, and hotel and catering services for 0.03% [1] - As of the report date, Yunnan Baiyao's market capitalization is 99.6 billion yuan [1]

Financial Performance - In the first three quarters of 2025, the company achieved operating revenue of CNY 30.654 billion, a year-on-year increase of 2.47% [2] - Net profit attributable to shareholders reached CNY 4.777 billion, exceeding the full-year 2024 figure of CNY 4.749 billion, with a year-on-year growth of 10.41% [2] - Non-recurring net profit was CNY 4.550 billion, surpassing the 2024 full-year figure of CNY 4.523 billion, reflecting a year-on-year increase of 6.68% [2] - The weighted average return on equity was 11.92%, up by 1.10 percentage points year-on-year [2] - Operating cash flow net amount reached CNY 4.456 billion, a year-on-year increase of 9.40% [2] - As of the end of the period, cash and cash equivalents totaled CNY 8.618 billion, with a debt-to-asset ratio of 25.36% [2] Pharmaceutical Business Development - The pharmaceutical division implemented integrated marketing strategies focusing on various scenarios, achieving over 20% growth in O2O sales [4] - Online sales during the 2025 "618" shopping festival saw significant improvements, with 48.45 million visitors and a GMV of CNY 254 million [4] - Clinical research on products like Yunnan Baiyao (powder) and capsules for diabetes foot and bone pain showed steady progress [4] Health Products Performance - The health products division maintained its leading market share in toothpaste, while the brand "Yangyuanqing" ranked first in Tmall for anti-hair loss shampoo during the 2025 "618" period [6] Acquisition and Integration Strategy - The acquisition of Juyitang aims to enhance the company's capabilities in the traditional Chinese medicine sector, with a production capacity of 25,000 tons for herbal pieces and 1,500 tons for formula granules [7] - Juyitang's established online sales channels and large B-end customer base are expected to provide strategic synergies and improve operational efficiency [7] Research and Development Pipeline - The company is focusing on secondary innovation and rapid drug development, with 16 major traditional Chinese medicine projects and 37 ongoing projects [8] - Key projects include the completion of Phase II clinical trials for Sanqi tablets and the initiation of Phase III trials for various products [8] - Long-term projects include the launch of clinical trials for innovative drugs and monoclonal antibody projects [8]

Group 1: Investor Relations Activity - The meeting was categorized as an analyst meeting and included one-on-one communication with various investment firms [2] - Participants included representatives from multiple investment firms and individual investors [2] Group 2: Meeting Details - The meeting took place on November 12, 2025, at the company's headquarters [2] - The main purpose of the meeting was to understand the company's production and operational status [2] Group 3: Attendees - Notable attendees included representatives from Jiangxi Zhifeng Consulting, Guangdong Zhenyuan Private Equity Fund, and other investment entities [2] - Company representatives included Zhang Yu, Yang Kexin, and Yu Yang from the investor relations management team [2]

Group 1: Investor Relations Activity - The meeting was categorized as a specific object survey [2] - Participants included representatives from various investment firms and individual investors [2] - The meeting took place on December 10, 2025, at the company's headquarters [2] Group 2: Purpose of the Meeting - The main objective was to understand the company's production and operational status [2]

Group 1: Health Products Business Performance - In the first half of 2025, the health products segment achieved revenue of 3.442 billion CNY, a year-on-year growth of 9.46% [2] - The segment focuses on a full-channel operation strategy, enhancing offline distribution and increasing online promotion efforts [2] - Key products include oral care toothpaste, which maintains a leading position, and hair care brand Yangyuanqing, which continues to grow driven by online sales [2][4] Group 2: Pharmaceutical Business Performance - The pharmaceutical segment reported a main business revenue of 4.751 billion CNY in the first half of 2025, with a year-on-year increase of 10.8% [5] - Sales of Yunnan Baiyao aerosol exceeded 1.453 billion CNY, showing a significant growth of over 20.9% [5] - Other traditional Chinese medicine products also saw notable growth, with sales of Qianling Jianpi Granules surpassing 100 million CNY and Pudilan Anti-inflammatory Tablets nearing 100 million CNY [5] Group 3: Traditional Chinese Medicine Resource Business - The traditional Chinese medicine resource segment generated external revenue of 914 million CNY in the first half of 2025, reflecting a year-on-year growth of approximately 6.3% [6] - The segment implements a "six unifications" operational model to enhance the traditional Chinese medicine industry chain [7] Group 4: R&D and Innovation Progress - The company emphasizes innovation-driven development, focusing on both traditional Chinese medicine and innovative drugs [8] - In the first half of 2025, the company initiated phase III clinical trials for the prostate cancer diagnostic nuclear drug project INR101, with 60 subjects enrolled [9] - The innovative drug project INR102 for prostate cancer treatment received clinical trial approval, and phase I trials have commenced [9] Group 5: Dividend Distribution - For the 2024 fiscal year, the company distributed a cash dividend of 11.85 CNY per 10 shares, totaling approximately 2.164 billion CNY [10] - The total cash dividend for 2024, including special dividends, amounted to 4.279 billion CNY, representing 90.09% of the net profit attributable to shareholders [10] - In the first half of 2025, the company distributed a cash dividend of 10.19 CNY per 10 shares, totaling 1.818 billion CNY, which accounted for 50.05% of the net profit for that period [10]

Group 1: Investor Relations Activity - The meeting was categorized as a specific object survey [2] - Participants included individual investors: Huang Kaiwei, Li Minggui, Chen Jiahe, Guo Hao, and Cui Weigang [2] - The meeting took place on December 10, 2025, at the Group's headquarters [2] Group 2: Company Overview - The main purpose of the investor relations activity was to understand the company's production and operational status [2] - Company representatives included Zhang Yu, Yang Kexin, and Yu Yang from the investor relations management team [2]

Group 1: Pharmaceutical Business Performance - In the first half of 2025, the pharmaceutical business group achieved a main business revenue of 4.751 billion yuan, a year-on-year increase of 10.8% [2] - Sales revenue of Yunnan Baiyao aerosol exceeded 1.453 billion yuan, with a significant year-on-year growth of over 20.9% [2] - Other core products, including Yunnan Baiyao plaster and capsules, also saw notable growth, contributing to the overall revenue increase [2] - Plant-based products, such as Qixue Kang oral liquid, reached sales of 202 million yuan, with a year-on-year growth of approximately 116.2% [2] Group 2: Health Product Channel Development - The company has established a comprehensive national sales team for health products, maintaining a leading market share in Yunnan Baiyao toothpaste [4] - Continuous optimization of the entire channel has strengthened traditional offline advantages while also focusing on emerging retail formats like instant retail and community group buying [4] Group 3: Traditional Chinese Medicine Cultivation Achievements - The company has implemented a precise research and transformation model for seed innovation, achieving coverage of ten major Yunnan medicinal sources [5] - The area of high-quality seed promotion has reached 90% of the annual target, with significant progress in the construction of "Yun Medicine Seed Valley" [5] - Over 7,000 acres of GAP management have been added for various medicinal herbs, integrating low-altitude economy and IoT technology [5] Group 4: Online Sales Performance - The pharmaceutical business group has expanded its online market, with O2O sales increasing by over 20% year-on-year [6] - During the 2025 "618" shopping festival, the company achieved a GMV of 254 million yuan through e-commerce platforms, attracting 48.45 million visitors [7] - Yunnan Baiyao toothpaste maintained the top market share in the domestic channel, while Yangyuan Qing ranked first in Tmall for anti-hair loss shampoo [7] Group 5: Nuclear Medicine Research Progress - The INR101 diagnostic nuclear medicine project has initiated Phase III clinical trials, with 32 research centers established and 60 subjects enrolled [8] - The INR102 therapeutic nuclear medicine project has received a clinical trial notification, with Phase I trials underway and 12 patients enrolled [8]

Group 1 - Yunnan Baiyao has undergone significant management changes, with Dong Ming stepping down as the legal representative and Wang Minghui resigning as chairman, replaced by Zhang Wenxue [1][2] - The registered capital of Yunnan Baiyao has increased from approximately 1.04 billion RMB to about 1.78 billion RMB [1][2] - The company was established in November 1993 and operates in various sectors including chemical raw materials, traditional Chinese medicine, and medical devices [1][3] Group 2 - The company is jointly held by Yunnan Provincial State-owned Assets Management Company, Xinhua Duhua Industrial Group Co., Ltd., and Yunnan Hehe Group Co., Ltd. [1][4] - The 11th Board of Directors meeting announced Zhang Wenxue as chairman and Dong Ming as vice chairman for a term of three years [1][2] - The company has a diverse business scope that includes sales of pharmaceuticals, medical devices, and technology consulting services [1][3]

据交易所数据显示，截至2025年12月5日收盘，云南白药（000538）报收于55.93元，上涨0.36%，换手 率0.27%，成交量4.72万手，成交金额2.64亿元。 资金流向方面，今日主力资金净流入4330.81万元，占比成交额16.43%。其中，超大单净流入228.63万 元、占成交额0.87%，大单净流入4102.18万元、占成交额15.56%，中单净流出流出1617.16万元、占成 交额6.13%，小单净流出2713.66万元、占成交额10.29%。 天眼查商业履历信息显示，云南白药集团股份有限公司，成立于1993年，位于昆明市，是一家以从事医 药制造业为主的企业。企业注册资本104139.9718万人民币，实缴资本43884.2484万人民币。公司法定代 表人为董明。 通过天眼查大数据分析，云南白药集团股份有限公司共对外投资了35家企业，参与招投标项目5000次， 知识产权方面有商标信息2375条，专利信息543条，此外企业还拥有行政许可1240个。 来源：市场资讯 云南白药最新一期业绩显示，截至2025三季报，公司营业总收入306.54亿元、同比增长2.47%，归属净 利润47.77亿元，同比 ...